Using antibodies in tumour immunotherapy

Expert Opinion on Biological Therapy

Volumn 4, Issue 8, 2004, Pages 1265-1284

  Schultes, Birgit C ^a   Nicodemus, Christopher F ^a  

^a Unither Pharmaceuticals   (United States)

Author keywords

Anti idiotype; Antibody; Bispecific mAb; Cancer therapy; Costimulary molecules; Cytokines; Dendritic cell; Immune complex; Immunotherapy; Oregovomab; Regulatory T cells; Vaccine; VEGF

Indexed keywords

ALEMTUZUMAB; ANTIBODY; ANTIIDIOTYPIC ANTIBODY; B7 ANTIGEN; BEVACIZUMAB; BISPECIFIC ANTIBODY; BREVAREX; CANCER VACCINE; CD28 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CETUXIMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EDRECOLOMAB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; INTERCELLULAR ADHESION MOLECULE 2; INTERLEUKIN 2 RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; OREGOVOMAB; RITUXIMAB; TRASTUZUMAB; VASCULOTROPIN ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTATION; B CELL LEUKEMIA; B CELL LYMPHOMA; BREAST CANCER; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; COLON CANCER; DENDRITIC CELL; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; LUNG SMALL CELL CANCER; MELANOMA; MULTIPLE MYELOMA; OVARY CANCER; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTIBODIES; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGEN-ANTIBODY COMPLEX; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS; CYTOKINES; DENDRITIC CELLS; GROWTH SUBSTANCES; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ACTIVE; LYMPHOCYTE ACTIVATION; NEOPLASM PROTEINS; NEOPLASMS; T-LYMPHOCYTES;

EID: 3442893072     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.8.1265     Document Type: Review

References (165)

1. KOHLER G, MILSTEIN C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 256(5517):495-497.
2. UPPENKAMP M, ENGERT A, DIEHL V, BUNJES D, HUHN D, BRITTINGER G: Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high-and low-grade non-Hodgkin's lymphomas: a multicenter Phase I/II study. Ann. Hematol. (2002) 81(1):26-32.
3. GRILLO-LOPEZ AJ, HEDRICK E, RASHFORD M, BENYUNES M: Rituximab: ongoing and future clinical development. Semin. Oncol (2002) 29(1 Suppl. 2):105-112.
4. YIP YL, WARD R: Anti-ErbB-2 monoclonal antibodies and ErbB-2 directed vaccines. Cancer Immunol. Immunother. (2002) 50(11):569-587.
5. SALTZ LB, MEROPOL NJ, LOEHRER PJ SR, NEEDLE MN, KOPIT J, MAYER RJ: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. (2004) 22(7):1201-1208.
6. HAMANN PR, HINMAN LM, HOLLANDER I et al.: Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug. Chem. (2002) 13(1):47-58.
7. GORDON LI, WITZIG TE, WISEMAN GA et al.: Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma. Semin. Oncol. (2002) 29(1 Suppl. 2):87-92.
8. KABBINAVAR F, HURWITZ HI, FEHRENBACHER L et al.: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. (2003) 21:60-65.
9. WILLETT CG, BOUCHER Y, DI TOMASO E et al.: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. (2004) 10:145-147.
10. PREHN RT, MAIN JM: Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. (1957) 18:769-778.
11. CHILDS R, CHERNOFF A, CONTENTIN N et al.: Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N. Engl. J. Med. (2000) 343(11):750-758. This report provides evidence for the tumour protective effect of GVHD in solid malignancy.
12. WEIDEN PL, FLOURNOY N, THOMAS ED et al.: Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med. (1979) 300(19):1068-1073.
13. JERNE N: Towards a network theory of the immune system. Ann. Immunol. (Paris) (1974) 125C:373-389. This paper provides an extensive description of the idiotypic network theory.
14. LINDEMAN J: Speculations on idiotypes of homebodies. Ann. Immunol. (Paris) (1973) 124:171-184.
15. MARUŠIC-GALEŠIC S, MARUŠIC M, POKRIC B: Cellular immune response to the antigen administered as an immune complex in vivo. Immunology (1992) 75:325-329.
16. MANCA F, FENOGLIO D, KUNKL A, CAMBIAGGI C, SASSO M, CELADA F: Differential activation of T cell clones stimulated by macrophages exposed to antigen complexed with monoclonal antibodies. J. Immunol. (1988) 140:2893-2898.
17. MANCA F, FENOGLIO D, LI PIRA G, KUNKL A, CELADA F: Effect of antigen/ antibody ratio on macrophage uptake, processing, and presentation to T cells of antigen complexed with polyclonal antibodies. J. Exp. Med. (1991) 173:37-48.
18. ROOSNEK E, LANZAVECCHIA A: Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells. J. Exp. Med. (1991) 173:487-489.
19. ROCK KL, BENACERRAF B, ABBAS AK: Antigen presentation by hapten-specific B lymphocytes. J. Exp. Med. (1984) 160:1102-1113.
20. LANZAVECCHIA A: Antigen-specific interaction between T and B cells. Nature (1985) 314:537-539.
21. COCCIA MA, BRAMS P: High titer, prostate specific antigen-specific human IgG production by hu-PBL-SCID mice immunized with antigen-mouse IgG2a complex-pulsed autologous dendritic cells. J. Immunol. (1998) 161:5772-5780.
22. TONY H-P, PARKER DC: Major histocompatibility complex-restricted, polyclonal B cell responses resulting from helper T cell recognition of antiimmunoglobulin presented by small B lymphocytes. J. Exp. Med. (1985) 161:223-241.
23. REGNAULT A, LANKAR D, LACABANNE V et al.: Fcγ receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I restricted antigen presentation after immune complex internalization. J. Exp. Med. (1999) 189:371-380. Early demonstration of the ability of antibodies to promote class I and class II antigen cross-presentation.
24. SERCARZ EE, LEHMANN PV, AMETANI A, BENICHOU G, MILLER A, MOUDGIL K: Dominance and crypticity of T cell antigenic determinants. Annu. Rev. Immunol. (1993) 11:729-766.
25. SCHULTES BC, AGOPSOWICZ K, BAUM RP et al.: Induction of CA125-specific B and T cell responses in MAb-B43.13 injected patients depends on complex formation of the MAb with circulating antigen. FASEB J. (2000) 14:Abstract 53.24.
26. KOVACSOVICS-BANKOWSKI M, ROCK KL: A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science (1995) 276:243-246.
27. PFEIFER JD, WICK MJ, ROBERTS RL, FINLAY K, NORMARK SJ, HARDING CV: Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature (1993) 361:359-362.
28. LANZAVECCHIA A: Mechanisms of antigen uptake for presentation. Curr. Opin. Immunol. (1996) 8:348-354. Comprehensive review on antigen-processing.
29. HEATH WR, CARBONE FR: Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. (2001) 19:47-64. Comprehensive summary of challenges to stimulating clinically relevant immunity.
30. WATTS C: Capture and processing of exogenous antigens for presentation on MHC molecules. Annu. Rev. Immunol. (1997) 15:821-850.
31. SCHULTES BC, AGOPSOWICZ K, KUZMA M, NICODEMUS CF, NOUJAIM AA, MANN DL: Antibody-antigen immune complexes allow for efficient MHC class I and II-restricted antigen presentation and maturation of dendritic cells: a novel strategy for cancer immunotherapy. Proc. Am. Assoc. Cancer Res. (2001) 42:276 (Abstract 1486).
32. RUIZ PJ, WOLKOWICZ R, WAISMAN A et al.: Idiotypic immunization induces immunity to mutated p53 and tumor rejection. Nat. Med. (1998) 4:710-712.
33. DURRANT LG, BUCKLEY DJ, ROBINS RA, SPENDLOVE I: 105Ad7 cancer vaccine stimulates anti-tumour helper and cytotoxic T-cell responses in colorectal cancer patients but repeated immunisations are required to maintain these responses. Int. J. Cancer (2000) 85:87-92.
34. SAHA A, CHATTERJEE SK, FOON KA, PRIMUS FJ, BHATTACHARYA-CHATTERJEE M: Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity. Cancer Res. (2003) 63:2844-2854.
35. PRIDE MW, SHUEY S, GRILLO-LOPEZ A et al.: Enhancement of cell-mediated immunity in melanoma patients immunized with murine anti-idiotypic monoclonal antibodies (MELIMMUNE) that mimic the high molecular weight proteoglycan antigen. Clin. Cancer Res. (1998) 4:2363-2370.
36. BERLYN KA, SCHULTES BC, LEVEUGLE B, NOUJAIM AA, ALEXANDER RB, MANN DL: Generation of CD4+ and CD8+ T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigemantibody) complexes. Clin. Immunol. (2001) 101:276-283.
37. RAVETCH JV, BOLLAND S: IgG Fc receptors. Annu. Rev. Immunol. (2001) 19:275-290. Comprehensive review on Fc receptors and their functions.
38. SCHUURHUIS DH, IOAN-FACSINAY A, NAGELKERKEN B et al.: Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J. Immunol. (2002) 168:2240-2246.
39. DHODAPKAR KM, KRASOVSKY J, WILLIAMSON B, DHODAPKAR MV: Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J. Exp. Med. (2002) 195(1):125-133. Demonstration that antibody-induced cross-presentation enhances generation of tumouricidal lymphocytes by DCs.
40. YADA A, EBIHARA S, MATSUMURA K et al.: Accelerated antigen presentation and elicitation of humoral response in vivo by FcgammaRIIB- and FcgammaRI/III-mediated immune complex uptake. Cell. Immunol. (2003) 225:21-32.
41. DEN HAAN JM, BEVAN MJ: Constitutive versus activation-dependent cross-presentation of immune complexes by CD8(+) and CD8(-) dendritic cells in vivo. Constitutive versus activation-dependent cross-presentation of immune complexes by CD8(+) and CD8(-) dendritic cells in vivo. J. Exp. Med. (2002) 196:817-827.
42. ENG H, KUZMA M, AGOPSOWICZ K, ZAROZINSKI C, SCHULTES BC: Opsonization with specific antibodies enhances dendritic cell presentation of apoptotic tumor cells and induction of CTL. 17th Annual Meeting of the Society of Biologic Therapy. San Diego, CA, USA (7-10 November 2002) (Abstract).
43. AKIYAMA K, EBIHARA S, YADA A et al.: Targeting apoptotic tumor cells to Fc gamma R provides efficient and versatile vaccination against tumors by dendritic cells. J. Immunol. (2003) 170:1641-1648.
44. ENG H, KUZMA ML, AGOPSOWlCZ K, ZAROZINSKI CC, SCHULTES BC: Complexation with murine MAb-B43.13 alters the endocytic trafficking of the mucinous tumor antigen CA125 after uptake by human dendritic cells. Keystone Symposium 'Dendritic Cells: Interfaces with Immunobiology and Medicine'. Keystone, CO, USA (3-8 March 2003) (Abstract).
45. HILTBOLD EM, VLAD AM, CIBOROWSKI P, WATKINS SC, FINN OJ: The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J. Immunol. (2000) 165:3730-3741.
46. SCHREIBER H, WU TH, NACHMAN J, KAST WM: Immunodominance and tumor escape. Semin. Cancer Biol. (2002) 12:25-31.
47. BITTON RJ: Cancer vaccines: a critical review on clinical impact. Curr. Opin. Mol. Ther. (2004) 6:17-26.
48. VAN OJIK HH, VALERIUS T: Preclinical and clinical data with bispecific antibodies recruiting myeloid effector cells for tumor therapy. Crit. Rev. Oncol. Hematol. (2001) 38:47-61.
49. WITHOFF S, HELFRICH W, DE LEIJ LF, MOLEMA G: Bi-specific antibody therapy for the treatment of cancer. Curr. Opin. Mol. Ther. (2001) 3:53-62.
50. KELER T, GUYRE PM, VITALE LA et al.: Targeting weak antigens to CD64 elicits potent humoral responses in human CD64 transgenic mice. J. Immunol. (2000) 165:6738-42.
51. HE LZ, RAMAKRISHNA V, CONNOLLY JE et al.: A novel human cancer vaccine elicits cellular responses to the tumor-associated antigen, human chorionic gonadotropin beta. Clin. Cancer Res. (2004) 10:1920-1927.
52. RAMAKRISHNA V, TREML JF, VITALE L et al.: Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules. J. Immunol. (2004) 172:2845-2852.
53. DESAI SA, WANG X, NORONHA EJ, FERRONE S: Structural relatedness of distinct determinants recognized by mAb TP25.99 on beta 2-μ associated with beta 2-μ free HLA class I heavy chains. J. Immunol. (2000) 165:3275-3283.
54. RUIZ PJ, WOLKOWICZ R, WAISMAN A et al.: Idiotypic immunization induces immunity to mutated p53 and tumor rejection. Nat. Med. (1998) 4:710-712.
55. FOON KA, BHATTACHARYA-CHATTERJEE M: Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res. (2001) 7:1112-1115.
56. FAGERBERG J, STEINITZ M, WIGZELL H, ASKELOF P, MELLSTEDT H: Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. Proc. Natl. Acad. Sci. USA (1995) 92:4773-4777.
57. DURRANT LG, DORAN M, AUSTIN EB, ROBINS RA: Induction of cellular immune responses by a murine monoclonal anti-idiotypic antibody recognizing the 791Tgp72 antigen expressed on colorectal, gastric and ovarian human tumors. Int. J. Cancer (1995) 61:62-66.
58. DURRANT LG, BUCKLEY DJ, ROBINS RA, SPENDLOVE I: 105AD7 cancer vaccine stimulated anti-tumor helper and cytotoxic T-cell responses in colorectal cancer patients but repeated immunizations are required to maintain these responses. Int. J. Cancer (2000) 85:87-92.
59. FOON KA, JOHN WJ, CHAKRABORTY M et al.: Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J. Clin. Oncol. (1999) 17:2889-2895.
60. FOON KA, LUTZKY J, BARAL RN et al.: Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J. Clin. Oncol. (2000) 18:376-384.
61. MITTELMAN A, CHEN ZJ, YANG H, WONG GY, FERRONE S: Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: Induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with sage IV melanoma. Proc. Natl. Acad. Sci. USA (1992) 89:466-470.
62. QUAN WD JR, DEAN GE, SPEARS L et al.: Active specific immunotherapy of metastatic melanoma with an anti-idiotype vaccine: A Phase I/II trial of I-Mel-2 plus SAF-m. J. Clin. Oncol. (1997) 15:2103-2110.
63. SALEH MN, LALISAN DY JR, PRIDE MW et al.: Immunologic response to the dual murine anti-id vaccine Melimmune-1 and Melimmune-2 in patients with high-risk melanoma without evidence of systemic disease. J. Immunother. (1998) 21:379-388.
64. REECE DE, FOON KA, BHATTACHARYA-CHATTERJEE M et al.: Use of the anti-idiotype antibody vaccine TriAb after autologous stem cell transplantation in patients with metastatic breast cancer. Bone Marrow Transplant. (2000) 26:729-735.
65. DÍAZ A, ALFONSO M, ALONSO R et al.: Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides. Clin. Immunol. (2003) 107:80-89.
66. GRANT SC, KRIS MG, HOUGHTON AN, CHAPMAN PB: Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotype antibody BEC2 plus Bacillus Calmette-Guerin. Clin. Cancer Res. (1999) 5:1319-1323.
67. REINARTZ S, KOHLER S, SCHLEBUSCH H et al.: Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (Phase Ib/II). Clin. Cancer Res. (2004) 10:1580-1587.
68. BHATNAGAR A, CARMICHAEL J, COSGRIFF T et al.: A randomized, double-blind, placebo controlled Phase III study of monoclonal antibody 3H1 plus 5-fluorouracil (5-FU)/leucovorin (LV) in stage IV colorectal carcinoma. Proc. Am. Soc. Clin. Oncol. (2003) 22:260 (Abstract 1041).
69. PUNT CJ, NAGY A, DOUILLARD JY et al.: Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet (2002) 360(9334):671-677.
70. RAGNHAMMAR P, FAGERBERG J, FRODIN JE, WERSALL P, HANSSON LO, MELLSTEDT H: Granulocyte/macrophage colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies. Cancer Immunol. Immunother. (1995) 40:367-375.
71. GORDON AN, SCHULTES BC, GALLION H et al.: CA125- and tumor-specific T cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. Gynecol. Oncol. (2004) 94:340-351.
72. BEREK JS, SCHULTES BC, NICODEMUS CF: Biologic and immunologic therapies for ovarian cancer. J. Clin. Oncol. (2003) 21(10 Suppl.):168s-174s.
73. BEREK JS, TAYLOR PT, GORDON AN, SCHULTES BC, WHITESIDE TL, NICODEMUS CF: Randomized pbo-controlled study of oregovomab (OV) for consolidation of clinical remission in pts with ovarian cancer (OC): prolonged disease-free survival (DFS) in optimal chemosensitive pts. Proc. Am. Soc. Clin. Oncol. (2003) 22:165 (Abstract 660).
74. RHA SY, TOLCHER AW, STEPHENSON J et al.: A Phase I study of BrevaRex, a murine monoclonal antibody directed at the MUC1 antigen, in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. (2000) 19:476a (Abstract 1868).
75. QI W, SCHULTES BC, LIU D, KUZMA M, DECKER W, MADIYALAKAN R: Characterization of an anti-MUC1 monoclonal antibody with potential as a cancer vaccine. Hybridoma (2001) 20:313-324.
76. MIYAZONO K, SUZUKI H, IMAMURA T: Regulation of TGF-beta signaling and its roles in progression of tumors. Cancer Sci. (2003) 94:220-224.
77. SIEGEL PM, MASSAGUE J: Cytostatic and apoptotic actions of TCP-beta in homeostasis and cancer. Nat. Rev. Cancer (2003) 3:807-821.
78. CHEN W, WAHL SM: TGF-beta: the missing link in CD4+CD25+ regulatory T cell-mediated immunosuppression. Cytokine Growth Factor Rev. (2003) 14:85-89.
79. AKDIS CA, BLASER K: Mechanisms of interleukin-10-mediated immune suppression. Immunology (2001) 103:131-136.
80. DUMONT N, ARTEAGA CL: Targeting the TGF-beta signaling network in human neoplasia. Cancer Cell (2003) 3:531-536.
81. MURAOKA RS, DUMONT N, RITTER CA et al.: Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. (2002) 109:1551-1559. Describes the use of a soluble inhibitor that binds and neutralises TGF-β to impair mammary tumour metastasis without accelerating mammary tumourigenesis in transgenic mice.
82. YANG YA, DUKHANINA O, TANG B et al.: Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects. J. Clin. Invest. (2002) 109:1607-1615. Soluble inhibitor that neutralises TGF-β was expressed as a transgene in the mammary glands of transgenic mice. Mammary tumourigenesis was not affected, but the ability of tumour cells to metastasise to the lungs was reduced. Interestingly, no evidence of inflammatory side effects was observed from the systemic distribution of TGF-β.
83. SAKAGUCHI S, SAKAGUCHI N, SHIMIZU J et al.: Immunologic tolerance maintained by CD25+CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. (2001) 182:18-32.
84. WOOD KJ, SAKAGUCHI S: Regulatory lymphocytes: regulatory T cells in transplantation tolerance. Nat. Rev. Immunol. (2003) 3:199-210.
85. VON HERRATH MG, HARRISON LC: Regulatory lymphocytes: antigen-induced regulatory T cells in autoimmunity. Nat. Rev. Immunol. (2003) 3:223-232.
86. SHEVACH EM: Regulatory T cells in autoimmunity. Annu. Rev. Immunol. (2000) 18:423-449. Comprehensive review on T reg.
87. TAYLOR PA, NOELLE RJ, BLAZAR BR: CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J. Exp. Med. (2001) 193:1311-1318.
88. TAYLOR PA, LEES CJ, BLAZAR BR: The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood (2002) 99:3493-3499.
89. BACH JF: Regulatory lymphocytes: regulatory T cells under scrutiny. Nat. Rev. Immunol. (2003) 3:189-198.
90. READ S, POWRIE F: CD4(+) regulatory T cells. Curr. Opin. Immunol. (2001) 13:644-649.
91. DIECKMANN D, PLOTTNER H, BERCHTOLD S, BERGER T, SCHULER G: Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J. Exp. Med. (2001) 193:1303-1310.
92. NG WF, DUGGAN PJ, PONCHEL F et al.: Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood (2001) 98:2736-2744.
93. LEVINGS MK, SANGREGORIO R, RONCAROLO MG: Human CD25(+)CD4(+) T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J. Exp. Med. (2001) 193:1295-1302.
94. WOO EY, CHU CS, GOLETZ TJ et al.: Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. (2001) 61:4766-4772.
95. WOO EY, YEH H, CHU CS et al.: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. (2002) 168:4272-4276.
96. LIYANAGE UK, MOORE TT, JOO H-G et al.: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. (2002) 169:2756-2761.
97. JONULEIT H, SCHMITT E, SCHULER G, KNOP J, ENK AH: Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. (2000) 192:1213-1222.
98. LEVINGS MK, SANGREGORIO R, SARTIRANA C et al.: Human CD25+CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells. J. Exp. Med. (2002) 196:1335-1346.
99. FONTENOT JD, GAVIN MA, RUDENSKY AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. (2003) 4:330-336.
100. LI L, HU P, KHAWLI LA, EPSTEIN AL: Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25+ T cell depletion. Cancer Res. (2003) 63:8384-8392.
101. SHIMIZU J, YAMAZAKI S, SAKAGUCHI S: Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. (1999) 163:5211-5218. One of the first reports demonstrating that removal of T reg with anti-CD25 antibodies can restore tumour immunity.
102. HERMANS IA, CHONG TW, PALMOWSKI MJ, HARRIS AL, CERUNDOLO V: Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res. (2003) 63:8408-8413.
103. TAKAHASHI T, TAGAMI T, YAMAZAKI S et al.: Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. (2000) 192:303-310.
104. ONIZUKA S, TAWARA I, SHIMIZU J, SAKAGUCHI S, FUJITA T, NAKAYAMA E: Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. (1999) 59:3128-3133.
105. AWAD M, NORTH RJ: Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T cells. Cancer Res. (1989) 49:1649-1654. Early report on the effect of cyclophosphamide on T reg.
106. SMITH JJ, MIHICH E, OZER H: In vitro effects of 4- hydroxyperoxycyclophosphamide on human immune regulatory T subset function. Methods Find. Exp. Clin. Pharmacol. (1987) 9:555-568.
107. SHIMIZU J, YAMAZAKI S, TAKAHASHI T, ISHIDA Y, SAKAGUCHI S: Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. (2002) 3:135-142.
108. MUELLER DL, JENKINS MK, SCHWARTZ RH: Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu. Rev. Immunol. (1989) 7:445-480. Comprehensive review on costimulatory pathways for T cell activation.
109. NAJAFIAN N, KHOURY SJ: T cell costimulatory pathways: blockade for autoimmunity. Expert Opin. Biol. Ther. (2003) 3:227-236.
110. HELLSTROM KE, HELLSTROM I: Therapeutic vaccination with tumor cells that engage CD137. J. Mol. Med. (2003) 81:71-86.
111. MURILLO O, ARINA A, TIRAPU I et al.: Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies. Clin. Cancer Res. (2003) 9:5454-6464. Recent review on immune modulating antibodies interacting with costimulatory molecules and inhibitory receptors on APCs and T cells.
112. VAN ELSAS A, HURWITZ AA, ALLISON JP: Combination immunotherapy of B16 melanoma using anti-CTLA-4 and GM-CSF producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. (1999) 190:355-366.
113. SALOMON B, BLUESTONE JA: Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Anna. Rev. Immunol. (2001) 19:225-252.
114. ORLEANS-LINDSAY JK, DERU A, CRAIG JI, PRENTICE HG, LOWDELL MW: In vitro co-stimulation with anti-CD28 synergizes with IL-12 in the generation of T cell immune responses to leukaemic cells; a strategy for ex-vivo generation of CTLs for immunotherapy. Clin. Exp. Immunol. (2003) 133:467-475.
115. SIEBELS M, MEYER G, HABICHT A, MEUER SC, MOEBIUS U.: Simultaneous ligation of CD5 and CD28 with monoclonal antibodies restores impaired immunostimulatory function in human renal cell carcinoma. Urol. Res. (2001) 29:330-337.
116. GOODWIN RG, DIN WS, DAVIS-SMITH T et al.: Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor. Eur. J. Immunol. (1993) 23:2631-2641.
117. KWON BS, HURTADO JC, LEE ZH et al.: Immune responses in 4-1BB (CD137)-deficient mice. J. Immunol. (2002) 168:5483-5490.
118. CROFT M: Costimulatory members of the TNFR family: keys to effective T-cell immunity? Nat. Rev. Immunol. (2003) 3:609-620.
119. WILCOX RA, FLIES DB, ZHU G et al.: Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J. Clin. Invest. (2002) 109:651-659.
120. MELERO I, SHUFORD WW, NEWBY SA et al.: Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. (1997) 3:682-685.
121. MELERO I, BACH N, HELLSTROM KE, ARUFFO A, MITTLER RS, CHEN L: Amplification of tumor immunity by gene transfer of the costimulatory 4-1BB ligand: synergy with the CD28 costimulatory pathway. Eur. J. Immunol. (1998) 28:1116-1121.
122. CHOI BK, BAE JS, CHOI EM et al.: 4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells. J. Leukoc. Biol. (2004) 75(5):785-791.
123. XU D, GU P, PAN PY, LI Q, SATO AI, CHEN SH: NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Int. J. Cancer (2004) 109:499-506.
124. HONG HJ, LEE JW, PARK SS et al.: A humanized anti-4-1BB monoclonal antibody suppresses antigen-induced humoral immune response in nonhuman primates. J. Immunother. (2000) 23:613-621.
125. TARABAN VY, ROWLEY TF, O'BRIEN L et al.: Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses. Eur. J. Immunol. (2002) 32:3617-3627.
126. CARRENO BM, COLLINS M: The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu. Rev. Immunol. (2002) 20:29-53.
127. GREWAL IS, FLAVELL RA: CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. (1998) 16:111-135. A comprehensive review of CD40/CD40L.
128. HUANG HI, WU PY, TEO CY et al.: Improved immunogenicity of a self tumor antigen by covalent linkage to CD40 ligand. Int. J. Cancer (2004) 108:696-703.
129. FRENCH RR, CHAN HT, TUTT AL, GLENNIE MJ: CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat. Med. (1999) 5:548-553.
130. HONEYCHURCH J, GLENNIE MJ, JOHNSON PW, ILLIDGE TM: Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma. Blood (2003) 102:1449-1457.
131. MURPHY WJ, WELNIAK L, BACK T, HIXON J et al.: Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses. J. Immunol. (2003) 170:2727-2733.
132. VAN MIERLO GJ, DEN BOER AT, MEDEMA JP et al.: CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity Proc. Natl. Acad. Sci. USA (2002) 99:5561-5566.
133. EGEN JG, KUHNS MS, ALLISON JP: CTLA-4: new insights into its biological function and use in tumor immunotherapy Nat. Immunol. (2002) 3:611-618. A comprehensive review of CTLA-4 blockade strategies.
134. LEACH D, KRUMMEL M, ALLISON JP: Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 271:1734-1736.
135. KWON ED, HURWITZ AA, FOSTER BA et al.: Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc. Natl. Acad. Sci. USA (1997) 94:8099-8103.
136. YANG Y, ZOU JP, MU J et al.: Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte associated molecule-4 blockade: The effect is manifested only at the restricted tumor-bearing stages. Cancer Res. (1997) 57:4036-4041.
137. SHRIKANT P, KHORUTS A, MESCHER MF: CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell and IL-2 dependent mechanism. Immunity (1999) 11:483-493.
138. SOTOMAYOR EM, BORRELLO IM, TUBB E, ALLISON JP, LEVITSKY HI: In vivo blockade of CTLA-4 enhances the priming of responsive T-cells but fails to prevent the induction of tumor antigen-specific tolerance. Proc. Natl. Acad. Sci. USA (1999) 96:11476-11481.
139. DRANOFF G, JAFFEE E, LAZENBYA et al.: Vaccination with irradiated tumor cells engineered to secrete GM-CSF stimulates potent, specific, and long lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA (1993) 90:3539-3543.
140. DAVIS TA, TCHEKMEDYIAN S, KORMAN A, KELER T, DEO Y, SMALL EJ: MDX-010 (human anti-CTLA4): a Phase I trial in hormone refractory prostate carcinoma (HRPC). Proc. Am. Soc. Clin. Oncol. (2002) 21:19a (Abstract 74).
141. TCHEKMEDYIAN S, GLASBY J, KORMAN A, KELER T, DEO Y, DAVIS TA: MDX-010 (human anti-CTLA4): a Phase I trial in malignant melanoma. Proc. Am. Soc. Clin. Oncol. (2002) 21:15a (Abstract 56).
142. KARANDIKAR NJ, VANDERLUGT CL, WALUNAS TL, MILLER SD, BLUESTONE JA: CTLA-4: A negative regulator of autoimmune disease. J. Exp. Med. (1996) 184:783-788.
143. PERRIN PJ, MALDONADO JH, DAVIS TA, JUNE CH, RACKE MK: CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J. Immunol. (1996) 157:1333-1336.
144. LÜHDER F, HÖGLUND P, ALLISON JP, BENOIST C, MATHIS D: Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J. Exp. Med. (1998) 187:427-432.
145. HODI FS, MIHM MC, SOIFFER RJ et al.: Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. USA (2003) 100:4712-4717.
146. PHAN GQ, YANG JC, SHERRY RM et al.: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA (2003) 100:8372-8377. This report demonstrates the synergistic effect of CTLA-4 blockade and vaccination.
147. MOKYR MB, KALINICHENKO T, GORELIK L, BLUESTONE JA: Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Res. (1998) 58:5301-5304.
148. NISHIMURA H, HONJO T: PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol. (2001) 22:265-268.
149. DONG H, STROME SE, SALOMAO DR et al.: Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. (2002) 8:793-800.
150. WINTTERLE S, SCHREINER B, MITSDOERFFER M et al.: Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res. (2003) 63:7462-7467.
151. SELENKO-GEBAUER N, MAJDIC O, SZEKERES A et al.: B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J. Immunol. (2003) 170:3637-3644.
152. CURIEL TJ, WEI S, DONG H et al.: Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. (2003) 9:562-567.
153. XU H, BICKFORD JK, LUTHER E, CARPENITO C, TAKEI F, SPRINGER TA: Characterization of murine intercellular adhesion molecule-2. J. Immunol. (1996) 156:4909-4914.
154. GEIJTENBEEK TB, KROOSHOOP DJ, BLEIJS DA et al.: DC-SIGN-ICAM-2 interaction mediates dendritic cell trafficking. Nat. Immunol. (2000) 1:353-357.
155. MELERO I, GABARI I, CORBI AL et al.: An anti-ICAM-2 (CD102) monoclonal antibody induces immune-mediated regressions of transplanted ICAM-2-negative colon carcinomas. Cancer Res. (2002) 62:3167-3174.
156. PEREZ OD, KINOSHITA S, HITOSHI Y et al.: Activation of the PKB/AKT pathway by ICAM-2. Immunity (2002) 16:51-65.
157. OHM JE, CARBONE DP: VEGF as a mediator of tumor-associated immunodeficiency. Immunol. Res. (2001) 23:263-272.
158. TAKAHASHI A, KONO K, ICHIHARA F, SUGAI H, FUJII H, MATSUMOTO Y: Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines. Cancer Immunol. Immunother. (2004) 53(6):543-550.
159. GABRILOVICH DI, CHEN HL, GIRGIS KR et al.: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. (1996) 2:1096-103.
160. HALL SS: A Commotion in the Blood: Life, Death, and the Immune System. Henry Holt and Company, Inc., New York, USA (1997). An historical summary of the cancer immunology field.
161. BODEY B, BODEY B JR, SIEGEL SE, KAISER HE: Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res. (2000) 20(4):2665-2676.
162. OLD LJ: Immunotherapy for cancer. Sci. Am. (1996) 275(3):136-143.
163. ZINKERNAGEL RM: Immunity against solid tumors? Int. J. Cancer (2001) 93(1):1-5.
164. ROSENBERG SA: Progress in human tumour immunology and immunotherapy. Nature (2001) 411(6835):380-384.
165. BANCHEREAU J, BRIERE F, CAUX C et al.: Immunobiology of dendritic cells. Annu. Rev. Immunol. (2000) 18:767-811.